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The South African Childhood Asthma Working Group (SACAWG), 
a subcommittee of the Allergy Society of South Africa (ALLSA), 
published the first national asthma guidelines for children in 1992.[1] 
Since then, the understanding of asthma and management strategies 
have evolved considerably. Asthma is now considered to be a 
spectrum of illness, reflecting different underlying inflammatory 
and airway processes.[2] Over the past two decades, the importance 
of airway inflammation underlying asthma pathogenesis (rather 
than bronchoconstriction) has been recognised, with guidelines 
increasingly focused on effectively controlling chronic asthma 
symptoms, as well as preventing acute exacerbations through inhaled 
therapy. 
These important asthma management recommendations have 
also been included in guidelines published by the Global Initiative 
for Asthma (GINA), which grew out of collaboration between the 
National Heart, Lung, and Blood Institute (NHLBI) and the World 
Health Organization (WHO).[3]
Local guidelines, based on international recommendations, and 
including acute exacerbation management, have filled an important 
role (Table 1).[4]
Asthma is the most common non-communicable disease in South 
Africa (SA).[5] Unfortunately, management groups and management 
strategies are competing for scarce healthcare resources, which also 
have to satisfy the needs of many serious and common communicable 
conditions, including HIV, tuberculosis (TB) and pneumonia. Despite 
these challenges, numerous successes have been facilitated for SA 
children with asthma, including widespread availability of inhaled 
corticosteroids (ICSs), spacer devices and many programmes to 
educate healthcare providers, asthmatic children and their caregivers. 
However, we have a long way to go in ensuring that every asthmatic 
child is well controlled and no longer suffers from asthma symptoms, 
which impact quality of life (Table 2). 
For many years, SA guidelines and international guidelines advocated 
a step-wise control scheme for drug selection for asthma control. 
This step-wise plan did not suggest that all asthmatics must start 
at step 1 and then escalate therapy as necessary. Rather, it provided 
a schematic way to reflect that asthma is a condition with various 
levels of expression and, therefore, therapies should be tailored to an 
individual patient’s level of morbidity. However, until recently, step 1 
was incorporated in all guidelines. It suggested that some asthmatics 
may have such mild asthma that they required only intermittent 
short-acting beta-2 agonist (SABA) bronchodilator treatment. 
Many insisted that this was such an uncommon scenario that its 
inclusion in guidelines allowed patients to use a form of therapy 
that was unproven, but also well known to cause harm.[6-9] This 
recommendation dates back more than 50 years, when asthma was 
thought to be primarily a disease of bronchoconstriction. However, 
it is now known that even mild or intermittent asthma is invariably 
associated with underlying airway inflammation. Therefore, in 2019, 
the GINA guidelines removed this step for adolescents and adults, 
recommending that an ICS always be used in conjunction with a 
bronchodilator.[10] An ICS-long-acting beta-2 agonist should be used 
either for symptoms (intermittently for mild asthma) or daily (to 
control asthma symptoms and reduce exacerbations) in adolescents. 
Unfortunately, data in children <12 years of age are still lacking, 
but we look forward to further evidence in children and revision of 
guidelines. In children 6 - 11 years of age, low-dose ICS or an ICS 
together with a SABA is recommended as the first step in the revised 
GINA guidelines. 
Asthma control is now the buzzword in asthma circles. Asthma 
control means the total absence of asthma symptoms, including 
night-time awakening, day-time cough or wheeze, exercise-induced 
symptoms, and no reliever therapy. Clearly, exacerbations are 
completely unacceptable, as these ‘lung attacks’ reduce lung function, 
and cause irreparable harm and death. Assessing asthma control 
should be the goal of a follow-up visit, but unfortunately this is 
often not done. Many scoring systems have been made available by 
companies and the National Asthma Education Programme (NAEP) 
(including the asthma control test).[11] Until we allow patients to 
share their ongoing symptoms in a safe and helpful manner, asthma 
continues to be a disease of significant morbidity.[12]
In addition to assessing asthma control, the most important 
aspect of asthma management is patient and parent education. The 
principles of an education plan are reflected in Table 3.
Finally, as a subgroup of ALLSA, we hope that the diseases 
associated with asthma and comorbid conditions are also adequately 
managed by healthcare practitioners. These include atopic dermatitis 
and allergic rhinitis. There are SA recommendations for the 
management of all allergic conditions,[14-16] but these need to be 
used alongside the recommendations, as asthma often co-exists with 
allergic conditions. 
We have lived through two waves of COVID-19 in SA, with a 
huge impact on our population, including children. Fortunately, the 
evidence suggests that children with stable asthma controlled on ICS 
therapy do not develop more severe COVID-19 symptoms than those 
without asthma.[17] However, viral infections are well known to trigger 
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Table 1. The value of local guidelines and recommendations
They are a summary of current evidence for disease management
They are written by ‘experts’ in the disease profile
They lead local health authority strategies for management
They have an impact on managed healthcare interventions
They provide a legal basis for adjudicating medicolegal claims
They provide a cost-effective strategy in line with local  
health conditions
They summarise care for busy practitioners
Table 2. Problems in managing childhood asthma
Presentation based on symptoms v. objective testing
Under-diagnosis and diagnosis in preschool children
Device usage by age
Adherence to therapy
More common triggers, e.g. upper-respiratory tract infections
Managing comorbidities, especially allergic rhinitis
Concern for systemic effects of inhaled corticosteroids
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asthma exacerbations. This is yet another reason why good asthma 
control is crucial in every asthmatic at this time. 
This issue of CME contains two articles reviewing aspects 
of paediatric asthma: a summary of new recommendations for 
asthma diagnosis and management,[18] 
and prevention of viral induced asthma 
exacerbations.[19] We trust that this update 
on recommendations for children with 
asthma will promote care for many children.
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Table 3. Elements of a successful asthma education plan[13]
Explain the inflammatory nature of the disease and need for regular control (adherence)
Describe and regularly check delivery methods for medication, especially nasal therapy and inhalers (technique)
Use of therapies for comorbid conditions
Treat flares and exacerbations
Monitor control of the disease
Regular check-ups
Avoid known allergens (including hidden sources) and irritants
Avoid unnecessary and unsafe therapies and practices
Provide written material or reputable web addresses for such access 
